BMYStock
Verdicts genuinely change. Free email alert the moment BMY's does — no target price to set, unlike a price alert.
Stable Ratio screen, 0 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
BMY is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant · status tracked since Nov 17, 2026
No change to BMY’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-06-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $120.2B as of 2026-10-20. At the 2026-11-18 close it is about $123.7B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 36.2% (37.3% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 7.1% (7.3% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 37.27% | 30.00% | Fail(7.3pp over) |
| Interest-bearing investments | 7.26% | 30.00% | Pass(22.7pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
Usmani Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 51.11% | 33.00% | Fail(18.1pp over) |
| Interest-bearing investments | 9.95% | 33.00% | Pass(23.0pp buffer) |
| Non-liquid assets | 67.65% | at least 20.00% | Pass(47.6pp above the floor) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
MSCI Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 51.11% | 33.33% | Fail(17.8pp over) |
| Cash + interest-bearing securities | 9.95% | 33.33% | Pass(23.4pp buffer) |
| Accounts receivable | 32.35% | 33.33% | Pass(1.0pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
FTSE Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 48.91% | 33.33% | Fail(15.6pp over) |
| Cash + interest-bearing securities | 9.95% | 33.33% | Pass(23.4pp buffer) |
| Accounts receivable | 32.35% | 50.00% | Pass(17.6pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
Dow Jones Islamic Market Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 42.09% | 33.00% | Fail(9.1pp over) |
| Cash + interest-bearing securities | 8.20% | 33.00% | Pass(24.8pp buffer) |
| Accounts receivable | 18.44% | 33.00% | Pass(14.6pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
S&P Shariah Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 44.77% | 33.00% | Fail(11.8pp over) |
| Cash + interest-bearing securities | 8.72% | 49.00% | Pass(40.3pp buffer) |
| Accounts receivable | 19.62% | 49.00% | Pass(29.4pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
MSCI M-Series Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 44.77% | 33.33% | Fail(11.4pp over) |
| Cash + interest-bearing securities | 8.72% | 33.33% | Pass(24.6pp buffer) |
| Accounts receivable | 28.34% | 49.00% | Pass(20.7pp buffer) |
| Non-permissible income | 1.22% | 5.00% | Pass(3.8pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from BMY's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $48.2B | 2025-12-31 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $42.9B | 2026-06-30 | LongTermDebtNoncurrent, LongTermDebtCurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $8.7B | 2026-06-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $87.6B | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $120.2B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $100.0B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $106.3B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $586.0M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-06-30. Income statement as of 2025-12-31. Screened 2026-10-20.
A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$87.6B
Assets· balance sheet as of 2026-06-30 -
Interest-bearing debt$42.9B
LongTermDebtNoncurrent, LongTermDebtCurrent· balance sheet as of 2026-06-30 -
Cash and interest-bearing securities$8.7B
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· balance sheet as of 2026-06-30 -
Receivables$19.6B
AccountsReceivableNetCurrent, ReceivablesNetCurrent· balance sheet as of 2026-06-30 -
Revenue$48.2B
Revenues· income statement as of 2025-12-31 -
Interest income (non-permissible)$586.0M
InvestmentIncomeInterest· income statement as of 2025-12-31 -
Market cap$120.2BMarket-data quote at screen time, 2026-10-20 · not a filing figure, so no link
What changed, and when
Verdict history for BMY. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for BMY has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Revenue by business segment
Not disclosed by segment: the latest 10-K (fiscal year ended 2025-12-31) does not tag its revenue by product, service or business segment in its XBRL, so there is no split to show. None is estimated.
Source: 10-K filed 2026-02-11 (accession 0000014272-26-000004), read from its XBRL on SEC EDGAR.
What would change the status
The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-06-30; market cap as stored on 2026-10-20.
No standard's deciding ratio sits within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio is $44.8B debt (operating leases included, as the screen counts it) over a market cap of $120.2B (as of 2026-10-20), 37.3% against a 30% line.
At the 2026-11-18 close the market cap is about $123.7B (the stored cap moved by the share price since), so this ratio would read 36.2%; the line is +21% from there. The published status changes only when the company is re-screened.
It would pass if the market cap rose above $149.3B (+24%), about $73.10 a share against $58.83 implied by the screen's own figures.
AAOIFI would then pass; the majority verdict would stay Not compliant (1 of 7 decided standards passing).
At the screen's market cap, it would take $8.7B less debt to clear the line.
AAOIFI would then pass; the majority verdict would stay Not compliant (1 of 7 decided standards passing, counting every standard that divides the same figure).
AAOIFI's investments ratio (7.3% against a 30% line) would only fail if the market cap fell by 76%, to $29.1B. At the 2026-11-18 close it would read 7.1%.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| LLYLilly(Eli) & Co | $1.2T | $1,382.75-2.32% |
| JNJJohnson & Johnson | $658.0B | — |
| ABBVAbbvie Inc | $467.4B | — |
| MRKMerck & Co Inc | $371.7B | — |
| NVSNovartis AG - ADR | $306.5B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold BMY
36 of the 260 funds whose filed holdings we currently hold own BMY shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns BMY.
You may already own itWidely held U.S. index funds. If you own one, you own BMY through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | BMY in fund | Fund compliant by weight |
|---|---|---|
| SCHD Schwab U.S. Dividend Equity ETF | 3.32% | 59% |
| VYM VANGUARD HIGH DIVIDEND YIELD INDEX FUND | 0.54% | 46% |
| RSP Invesco S&P 500 Equal Weight ETF | 0.23% | 44% |
| SCHB Schwab U.S. Broad Market ETF | 0.18% | 53% |
| SPY | 0.18% | 56% |
| VOO VANGUARD 500 INDEX FUND | 0.18% | 56% |
| SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 0.18% | 56% |
| IVV iShares Core S&P 500 ETF | 0.18% | 56% |
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.16% | 54% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.16% | 54% |
| Fund | BMY in fund | Fund compliant by weight |
|---|---|---|
| FGIPX Nomura Growth and Income Fund | 2.98% | 42% |
| LVAFX LSV Global Managed Volatility Fund | 1.99% | 25% |
| POSKX PRIMECAP Odyssey Stock Fund | 1.75% | 55% |
| MPISX BNY Mellon Income Stock Fund | 1.61% | 36% |
| LVAMX LSV U.S. Managed Volatility Fund | 1.16% | 31% |
| TLORX Transamerica Large Value Opportunities | 1.12% | 40% |
| LVAVX LSV Conservative Value Equity Fund | 0.96% | 34% |
| DEW WisdomTree Global High Dividend Fund | 0.86% | 26% |
| PQUS Pictet AI Enhanced US Equity ETF | 0.77% | 53% |
| PRFDX T. Rowe Price Equity Income Fund | 0.65% | 32% |
16 more funds
| Fund | BMY in fund | Fund compliant by weight |
|---|---|---|
| PRXV Praxis Impact Large Cap Value ETF | 0.52% | 50% |
| ILCV iShares Morningstar Value ETF | 0.39% | 40% |
| GMLGX GuideMark Large Cap Core Fund | 0.38% | 48% |
| QUS State Street(R) SPDR(R) MSCI USA StrategicFactors(SM) ETF | 0.33% | 55% |
| TLACX Transamerica Large Core ESG Also TLARX | 0.27% | 58% |
| TRMVX SIMT Large Cap Value Fund | 0.26% | 30% |
| TRPSX Nuveen Large Cap Responsible Equity Fund | 0.21% | 65% |
| XTR Global X S&P 500 Tail Risk ETF | 0.21% | 53% |
| NEIAX Columbia Large Cap Index Fund | 0.20% | 54% |
| CRBN iShares Low Carbon Optimized MSCI ACWI ETF | 0.20% | 50% |
| USPX Franklin U.S. Equity Index ETF | 0.18% | 56% |
| PREIX T. Rowe Price Equity Index 500 Fund | 0.18% | 54% |
| URTH iShares MSCI World ETF | 0.15% | 51% |
| LGH HCM Defender 500 Index ETF | 0.14% | 46% |
| TRSGX T. Rowe Price Spectrum Moderate Growth Allocation Fund | 0.11% | not computed |
| RIFAX U.S. Strategic Equity Fund | 0.08% | not computed |
Sorted by BMY’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names BMY once, so a bond is not counted as the shares; 1 more fund name BMY in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | $889M | 2.6% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $444M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $216M | 0.1% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $149M | 0.2% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $109M | 0.1% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $71M | 0.1% | 2026-09-30 |
| John Rogers | Ariel Investments | $41M | 0.4% | 2026-09-30 |
| Jeremy Grantham | GMO | $29M | 0.1% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $26M | 0.2% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $17M | 0.0% | 2026-09-30 |
| Ken Fisher | Fisher Asset Management | $13M | 0.0% | 2026-09-30 |
| Kahn Brothers | Kahn Brothers Group | $10M | 1.6% | 2026-09-30 |
| Mario Gabelli | GAMCO Investors | $5M | 0.1% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $5M | 0.0% | 2026-09-30 |
| Bill Miller | Miller Value Partners | $4M | 0.9% | 2026-09-30 |
| Tweedy, Browne | Tweedy, Browne Company | $3M | 0.2% | 2026-09-30 |
| Mark Hillman | Hillman Capital Management | $2M | 1.9% | 2026-09-30 |
| Lee Ainslie | Maverick Capital | $2M | 0.0% | 2026-09-30 |
| Mairs & Power | Mairs & Power | $2M | 0.0% | 2026-09-30 |
| Dodge & Cox | Dodge & Cox | $1M | 0.0% | 2026-09-30 |
| Jeff Auxier | Auxier Asset Management | $1M | 0.2% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $1M | 0.0% | 2026-09-30 |
| Sallie Krawcheck | Ellevest | $1M | 0.1% | 2026-09-30 |
| Sarah Ketterer | Causeway Capital Management | $0M | 0.0% | 2026-09-30 |
| Peter Schiff | Euro Pacific Asset Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.10 | NEUTRAL |
| Stochastic %K (14) | 1.32 | BUY |
| CCI (20) | -186.82 | BUY |
| Williams %R (14) | -98.68 | BUY |
| MACD (12,26,9) | -0.22 | SELL |
| ROC (10) | -7.21 | SELL |
| Momentum (10) | -4.63 | SELL |
| EMA (10) | 61.90 | SELL |
| SMA (10) | 62.27 | SELL |
| EMA (20) | 61.90 | SELL |
| SMA (20) | 62.19 | SELL |
| EMA (30) | 61.83 | SELL |
| SMA (30) | 61.26 | SELL |
| EMA (50) | 61.78 | SELL |
| SMA (50) | 61.45 | SELL |
| EMA (100) | 61.09 | SELL |
| SMA (100) | 61.97 | SELL |
| EMA (200) | 58.68 | BUY |
| SMA (200) | 59.46 | BUY |
About BMY
Healthcare · Drug Manufacturers - General
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 45 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
BEARISH 0 buys · 1 sells
Recent: Holzer Phil M sold 16862 sh @ $67.50 (2026-08-25)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.